Literature DB >> 29925953

Codon-specific translation reprogramming promotes resistance to targeted therapy.

Francesca Rapino1,2, Sylvain Delaunay1,2, Florian Rambow3,4, Zhaoli Zhou1,2, Lars Tharun5, Pascal De Tullio6, Olga Sin7,8,9, Kateryna Shostak2,10, Sebastian Schmitz1,2, Jolanda Piepers11, Bart Ghesquière12, Latifa Karim2,13, Benoit Charloteaux2,13, Diane Jamart1,2, Alexandra Florin5, Charles Lambert2, Andrée Rorive14, Guy Jerusalem14, Eleonora Leucci3,4, Michael Dewaele3,4, Marc Vooijs11, Sebastian A Leidel7,8,9, Michel Georges2,13, Marianne Voz2, Bernard Peers2, Reinhard Büttner5, Jean-Christophe Marine3,4, Alain Chariot2,10,15, Pierre Close16,17,18.   

Abstract

Reprogramming of mRNA translation has a key role in cancer development and drug resistance 1 . However, the molecular mechanisms that are involved in this process remain poorly understood. Wobble tRNA modifications are required for specific codon decoding during translation2,3. Here we show, in humans, that the enzymes that catalyse modifications of wobble uridine 34 (U34) tRNA (U34 enzymes) are key players of the protein synthesis rewiring that is induced by the transformation driven by the BRAF V600E oncogene and by resistance to targeted therapy in melanoma. We show that BRAF V600E -expressing melanoma cells are dependent on U34 enzymes for survival, and that concurrent inhibition of MAPK signalling and ELP3 or CTU1 and/or CTU2 synergizes to kill melanoma cells. Activation of the PI3K signalling pathway, one of the most common mechanisms of acquired resistance to MAPK therapeutic agents, markedly increases the expression of U34 enzymes. Mechanistically, U34 enzymes promote glycolysis in melanoma cells through the direct, codon-dependent, regulation of the translation of HIF1A mRNA and the maintenance of high levels of HIF1α protein. Therefore, the acquired resistance to anti-BRAF therapy is associated with high levels of U34 enzymes and HIF1α. Together, these results demonstrate that U34 enzymes promote the survival and resistance to therapy of melanoma cells by regulating specific mRNA translation.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29925953     DOI: 10.1038/s41586-018-0243-7

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  81 in total

1.  Can Protein Expression Be Regulated by Modulation of tRNA Modification Profiles?

Authors:  Leticia Pollo-Oliveira; Valérie de Crécy-Lagard
Journal:  Biochemistry       Date:  2018-12-18       Impact factor: 3.162

Review 2.  uORF-mediated translational control: recently elucidated mechanisms and implications in cancer.

Authors:  Hung-Hsi Chen; Woan-Yuh Tarn
Journal:  RNA Biol       Date:  2019-06-24       Impact factor: 4.652

3.  Translational offsetting as a mode of estrogen receptor α-dependent regulation of gene expression.

Authors:  Julie Lorent; Eric P Kusnadi; Vincent van Hoef; Richard J Rebello; Matthew Leibovitch; Johannes Ristau; Shan Chen; Mitchell G Lawrence; Krzysztof J Szkop; Baila Samreen; Preetika Balanathan; Francesca Rapino; Pierre Close; Patricia Bukczynska; Karin Scharmann; Itsuhiro Takizawa; Gail P Risbridger; Luke A Selth; Sebastian A Leidel; Qishan Lin; Ivan Topisirovic; Ola Larsson; Luc Furic
Journal:  EMBO J       Date:  2019-09-26       Impact factor: 11.598

4.  A tRNA modification balances carbon and nitrogen metabolism by regulating phosphate homeostasis.

Authors:  Ritu Gupta; Adhish S Walvekar; Shun Liang; Zeenat Rashida; Premal Shah; Sunil Laxman
Journal:  Elife       Date:  2019-07-01       Impact factor: 8.140

5.  A wobbly road to drug resistance in melanoma: tRNA-modifying enzymes in translation reprogramming.

Authors:  Mary McMahon; Davide Ruggero
Journal:  EMBO J       Date:  2018-07-02       Impact factor: 11.598

6.  Translation regulation in skin cancer from a tRNA point of view.

Authors:  Katerina Grafanaki; Dimitrios Anastasakis; George Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; Constantinos Stathopoulos
Journal:  Epigenomics       Date:  2018-12-19       Impact factor: 4.778

7.  Queuing up the ribosome: nutrition and the microbiome control protein synthesis.

Authors:  Itamar Kozlovski; Reuven Agami
Journal:  EMBO J       Date:  2018-09-03       Impact factor: 11.598

8.  Generally applicable transcriptome-wide analysis of translation using anota2seq.

Authors:  Christian Oertlin; Julie Lorent; Carl Murie; Luc Furic; Ivan Topisirovic; Ola Larsson
Journal:  Nucleic Acids Res       Date:  2019-07-09       Impact factor: 16.971

Review 9.  Pathways to disease from natural variations in human cytoplasmic tRNAs.

Authors:  Jeremy T Lant; Matthew D Berg; Ilka U Heinemann; Christopher J Brandl; Patrick O'Donoghue
Journal:  J Biol Chem       Date:  2019-01-14       Impact factor: 5.157

10.  ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells.

Authors:  Peter Cruz-Gordillo; Megan E Honeywell; Nicholas W Harper; Thomas Leete; Michael J Lee
Journal:  Sci Signal       Date:  2020-11-17       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.